Galectin Therapeutics Inc. (GALT)

[Tesla1]

Darwinian: I agree with you that OCA will be very expensive and GRMD02 should have definite cost advantages. My point is really, I don't believe that OCA will have much utility for later stage fibrosis. It will only be for earlier stage disease (IMO). I think that the more valuable part of the market will prove to be treating patients with stage 2, 3 or 4 liver fibrosis because prior to that patients likely do not even know that they even have NASH. ALL IMO.